Editas Medicine Announces Second Quarter 2017 Results and Update – Nasdaq
Nasdaq |
Editas Medicine Announces Second Quarter 2017 Results and Update
Nasdaq Strengthened unmatched intellectual property position with issuance of first patent for CRISPR/Cpf1. In May, the European Patent Office issued the first patent for CRISPR/Cpf1, which is exclusively licensed to Editas Medicine. CRISPR/Cpf1 offers … |
